reMYND receives license renewal from Schering-Plough for RadarScreen
Leuven, Belgium - 18 November 2009
reMYND NV ('reMYND') announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic
compounds in early stage drug discovery.
RadarScreen allows high-throughput identification of genotoxic liabilities, such as the induction of
chromosomal breaks and DNA mutations, of compounds and their corresponding metabolites. It is a yeast-based technology comprising a fast, reproducible and highly robust enzymatic assay for costeffective screening in a standard laboratory environment. In contrast with currently available tests,
these characteristics permit extensive genotoxicity assessments early in the development process, already at the hit identification stage. As such RadarScreen provides guidance to chemical optimization and may prevent later stage failures. reMYND has developed and validated RadarScreen
over the past few years and is licensing-out this technology to the pharma, biotech, food, environmental, cosmetics and chemical industries. reMYND is currently also developing ready-to-use
kits in the form of 384-well-plates in collaboration with BioPredic International, based in France.
According to An Tanghe, reMYND's Business Developer, 'RadarScreen has been developed by
reMYND's scientists to address a clear need: the ability to screen for genotox liabilities early in reMYND's own drug discovery process. The promising validation data obtained in-house and at Schering-Plough have triggered the decision to out-license the technology. Schering-Plough has been
using RadarScreen for one year now and we are delighted about their enthusiasm. I have a firm belief, though, that not only the pharmaceutical industry can benefit from using RadarScreen.
There are ample other industries for which elimination of genotoxic compounds at an early stage is essential, for instance food, environmental and cosmetics. Moreover, RadarScreen can play a pivotal role in helping the chemical industry to comply with the recently introduced REACH-legislation that
gives greater responsibility to industry to manage the risks from chemicals and provide safety
information on the substances '
For more info, please contact:
NV reMYND
Dr. An Tanghe
Business Developer Contract Research
Tel: +32 16 75 14 22
Fax: +32 16 75 14 21
radarscreen@remynd.be
http://www.remynd.com
About reMYND NV
reMYND NV, based in Leuven, Belgium, actively drives the development of disease modifying
treatments against Alzheimer's Disease and Parkinson's Disease, either through its own Drug Discovery&Development (DDD) or as a Contract Research Organization (CRO). reMYND NV is
privately owned and was founded in 2002 as a spin-off of the University of Leuven. The CRO mainly focuses on Alzheimer transgenic mouse models with amyloid (APP London mutation) and/or Tau pathology. The DDD Unit focuses on Tau (AD) and á-synuclein (PD) as targets. The lead PD program is
ready to enter Phase 1, while the lead AD program is planned to enter clinical testing in 2011.
About Biopredic International
Biopredic International, based in Rennes, France, is a provider of ethically-obtained and difficult to locate human and animal cells, tissue, and blood used in discovery and development of drugs, including very unique human liver cells such as the HepaRG®cells and primary hepatocytes, human
skin sheets and human bio-fluids.
reMYND NV ('reMYND') announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic
compounds in early stage drug discovery.
RadarScreen allows high-throughput identification of genotoxic liabilities, such as the induction of
chromosomal breaks and DNA mutations, of compounds and their corresponding metabolites. It is a yeast-based technology comprising a fast, reproducible and highly robust enzymatic assay for costeffective screening in a standard laboratory environment. In contrast with currently available tests,
these characteristics permit extensive genotoxicity assessments early in the development process, already at the hit identification stage. As such RadarScreen provides guidance to chemical optimization and may prevent later stage failures. reMYND has developed and validated RadarScreen
over the past few years and is licensing-out this technology to the pharma, biotech, food, environmental, cosmetics and chemical industries. reMYND is currently also developing ready-to-use
kits in the form of 384-well-plates in collaboration with BioPredic International, based in France.
According to An Tanghe, reMYND's Business Developer, 'RadarScreen has been developed by
reMYND's scientists to address a clear need: the ability to screen for genotox liabilities early in reMYND's own drug discovery process. The promising validation data obtained in-house and at Schering-Plough have triggered the decision to out-license the technology. Schering-Plough has been
using RadarScreen for one year now and we are delighted about their enthusiasm. I have a firm belief, though, that not only the pharmaceutical industry can benefit from using RadarScreen.
There are ample other industries for which elimination of genotoxic compounds at an early stage is essential, for instance food, environmental and cosmetics. Moreover, RadarScreen can play a pivotal role in helping the chemical industry to comply with the recently introduced REACH-legislation that
gives greater responsibility to industry to manage the risks from chemicals and provide safety
information on the substances '
For more info, please contact:
NV reMYND
Dr. An Tanghe
Business Developer Contract Research
Tel: +32 16 75 14 22
Fax: +32 16 75 14 21
radarscreen@remynd.be
http://www.remynd.com
About reMYND NV
reMYND NV, based in Leuven, Belgium, actively drives the development of disease modifying
treatments against Alzheimer's Disease and Parkinson's Disease, either through its own Drug Discovery&Development (DDD) or as a Contract Research Organization (CRO). reMYND NV is
privately owned and was founded in 2002 as a spin-off of the University of Leuven. The CRO mainly focuses on Alzheimer transgenic mouse models with amyloid (APP London mutation) and/or Tau pathology. The DDD Unit focuses on Tau (AD) and á-synuclein (PD) as targets. The lead PD program is
ready to enter Phase 1, while the lead AD program is planned to enter clinical testing in 2011.
About Biopredic International
Biopredic International, based in Rennes, France, is a provider of ethically-obtained and difficult to locate human and animal cells, tissue, and blood used in discovery and development of drugs, including very unique human liver cells such as the HepaRG®cells and primary hepatocytes, human
skin sheets and human bio-fluids.
Subscribe to our newsletter
Stay tuned and get our news in your inbox: subscribe here.
Keep me informed
